**JB Chemicals & Pharmaceuticals Limited (JBCHEPHARM) Investment Report**

**Date:** October 26, 2024


**1. Company Overview**

JB Chemicals & Pharmaceuticals Limited (JBCHEPHARM) is a pharmaceutical company listed on the NSE (National Stock Exchange of India) since April 29, 2003.  The company operates within the Pharmaceuticals industry and holds a position within the mid-cap segment of the Indian pharmaceutical market.  Further details on its specific market niche and competitive landscape would require additional research beyond the provided data.


**2. Market Data Analysis**

| Metric                     | Value          | Notes                                                                 |
|-----------------------------|-----------------|-------------------------------------------------------------------------|
| Current Price               | 1,871.50        | As of the last update in the provided data.                           |
| Percentage Change (PChange) | -2.18%          | Negative change indicating a recent price decline.                     |
| Pre-Open Activity          | 1,916.50 (Open) |  Pre-open price was higher than the closing price, suggesting potential buying interest.  However, the final pre-open price was not significantly higher than the previous close. |
| Week High                   | 2,030.00        | Indicates recent price volatility.                                      |
| Week Low                    | 1,435.00        | Significant week-to-week price fluctuation.                             |
| VWAP                        | 1,894.66        | Volume Weighted Average Price suggests a relatively stable price range. |
| Sector PE                   | 48.69           | Industry Price-to-Earnings ratio.                                      |
| Symbol PE                   | 48.69           | Company's Price-to-Earnings ratio, indicating valuation relative to earnings. |
| Delivery Percentage         | 58.91%          | Relatively high delivery percentage suggests some degree of conviction in buying. |
| Market Depth                | Limited Data    | The provided order book data shows zero buy and sell quantities, which is unusual and may indicate incomplete or delayed data. Further investigation is needed. |


**3. Financial Performance**

The provided financial data shows a consistent profit after tax (PAT) and earnings per share (EPS) over the last five quarters. However, the data is limited and does not allow for a comprehensive analysis of financial health.  Further analysis would require access to complete financial statements.

| Quarter      | Revenue     | Expenses    | Profit After Tax | EPS (Diluted) |
|--------------|-------------|-------------|-------------------|----------------|
| Q3 FY25      | 96,465      | 73,045      | 17,312            | 11.15           |
| Q2 FY25      | 95,747      | 72,326      | 17,323            | 11.16           |
| Q1 FY25      | 82,530      | 66,219      | 12,585            | 8.11            |
| Q4 FY24      | 80,671      | 63,030      | 12,792            | 8.25            |
| Q3 FY24      | 84,360      | 64,288      | 14,502            | 9.36            |


**Key Financial Ratios:**  Cannot be calculated with the limited data provided.  Further information is needed to calculate key ratios such as Return on Equity (ROE), Return on Assets (ROA), Debt-to-Equity ratio, etc.


**4. Corporate Actions and Announcements**

JB Chemicals has a history of consistent dividend payouts and has recently undertaken a face value split.  Recent announcements include updates on capital alteration and fund raising, as well as information regarding ESOPs (Employee Stock Ownership Plans).  The frequency of announcements suggests active corporate activity.


**5. Shareholding Patterns**

| Quarter      | Promoter & Promoter Group | Public | Shares held by Employee Trusts | Total |
|--------------|---------------------------|--------|-------------------------------|-------|
| 30-Sep-2023  | 53.86%                     | 46.14% | 0.00%                         | 100.00%|
| 31-Dec-2023  | 53.83%                     | 46.17% | 0.00%                         | 100.00%|
| 31-Mar-2024  | 53.78%                     | 46.22% | 0.00%                         | 100.00%|
| 30-Jun-2024  | 53.77%                     | 46.23% | 0.00%                         | 100.00%|
| 30-Sep-2024  | 53.74%                     | 46.26% | 0.00%                         | 100.00%|

Promoter holding has shown a slight downward trend over the past year, while public holding has correspondingly increased. This is a relatively minor change and doesn't necessarily indicate a significant negative factor.


**6. Volatility and Risk Assessment**

The stock exhibits significant volatility, as evidenced by the week high and low prices.  The CM Annual Volatility of 34.2% further confirms this high volatility.  The risk-reward profile is therefore considered high risk/high reward.  A more detailed risk assessment would require a longer historical price data set and analysis of macroeconomic factors affecting the pharmaceutical sector.


**7. Advantages of Buying the Stock**

* Consistent dividend payouts.
* Relatively high delivery percentage in recent trades.
* Active corporate actions suggest management is proactive.
* Consistent profitability (based on limited data).


**8. Disadvantages and Risks**

* High volatility.
* Limited market depth data available.
* Dependence on the pharmaceutical sector's performance and regulatory environment.
*  Slight decline in promoter holding.


**9. Investment Horizon Recommendations**

* **Short-Term (less than 3 months): Hold.** The recent price decline and limited market depth data make a short-term buy less attractive.  Waiting for clearer market signals is advisable.

* **Medium-Term (3 to 12 months): Hold.**  The consistent dividend payouts and generally positive financial performance (based on limited data) suggest a hold strategy.  However, continued monitoring of market conditions and financial results is crucial.

* **Long-Term (1 year and beyond): Hold.**  The company's consistent dividend history and generally positive financial performance (subject to further verification with complete financial statements) make it a potential long-term hold.  However, long-term investors should carefully consider the inherent volatility of the stock.


**10. Stock and Analysis Scoring**

**Stock Score (out of 10): 6.5**

* Financial Health: 7/10 (Based on limited data showing consistent profitability, but further analysis is needed.)
* Market Performance: 6/10 (High volatility and recent price decline offset positive aspects.)
* Volatility and Risk: 4/10 (High volatility is a significant risk factor.)
* Corporate Actions & Governance: 8/10 (Consistent dividends and active corporate actions are positive.)
* Shareholding Patterns: 7/10 (Slight decline in promoter holding is a minor concern.)


**Analysis Score (out of 10): 7/10**

* Completeness and Utilization of Data: 6/10 (Some data was incomplete or unavailable, limiting the analysis.)
* Accuracy and Clarity of Analysis: 8/10 (Analysis was clear and well-structured given the data limitations.)
* Professional Formatting: 9/10 (Report is well-formatted and easy to read.)


**11. Professional Recommendation Summary**

Based on the available data, JBCHEPHARM is recommended as a **Hold** for short, medium, and long-term investment horizons.  The high volatility presents a significant risk, but the consistent dividend payouts and generally positive financial performance (subject to further verification) offer potential rewards.  However,  a more comprehensive analysis using complete financial statements and a deeper dive into market depth and sector analysis is strongly recommended before making any investment decisions.  The limited market depth data is a significant concern and requires further investigation.
